This is an example page. It’s different from a blog post because it will stay in one place and will show up in your site navigation (in most themes). Most people start with an About page that introduces them to potential site visitors. It might say something like this:
Hi there! I’m a bike messenger by day, aspiring actor by night, and this is my website. I live in Los Angeles, have a great dog named Jack, and I like piña coladas. (And gettin’ caught in the rain.)
…or something like this:
The XYZ Doohickey Company was founded in 1971, and has been providing quality doohickeys to the public ever since. Located in Gotham City, XYZ employs over 2,000 people and does all kinds of awesome things for the Gotham community.
As a new WordPress user, you should go to your dashboard to delete this page and create new pages for your content. Have fun!
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy
This is a single-arm, non-randomized prospective trial designed to assess the effectiveness and safety of the HistoSonics System, a novel treatment for primary or metastatic liver tumors. The trial aims to evaluate how well the system works and its safety profile in targeting liver tumors.
Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal Melanoma Patients (PLUME)
This Phase II, single-centre trial aims to evaluate the combination of pembrolizumab and lenvatinib in patients with metastatic uveal melanoma (UM). Researchers suspect that prior treatment with Tebentafusp may influence the effectiveness of anti-PD-1 therapies. To investigate this, the study will include two separate groups:
- Cohort 1: Patients who have not previously received Tebentafusp.
- Cohort 2: Patients who have been treated with Tebentafusp in the past.
Both cohorts will receive the same treatment, and the study will monitor tumour response through liver MRI and chest-abdomen-pelvis CT scans every 9 weeks until disease progression. After treatment ends, a follow-up visit will take place within 28 days, and patient survival status will be tracked after discontinuation.
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and with Pembrolizumab
This Phase 1/2, first-in-human, open-label, multicenter study aims to determine the safest and most effective dose (Maximum Tolerated Dose, MTD, or Recommended Phase 2 Dose, RP2D) of LNS8801, both on its own and in combination with pembrolizumab. Using a 3+3 dose escalation design, the study will evaluate the safety, tolerability, how the drug behaves in the body (pharmacokinetics), and its ability to fight tumours.
The trial includes three stages: a dose escalation phase to find the optimal dose, a dose expansion phase to further test the treatment, and Phase 2A cohorts to assess its effectiveness in specific patient groups. Up to 200 patients will take part, and the study will be conducted at up to 15 sites across the United States.
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Study of Roginolisib in UM Patients (OCULE-01)
This Phase II study is being conducted at multiple centres to evaluate the effectiveness of a drug called Roginolisib in treating advanced or metastatic ocular/uveal melanoma. The study is open-label, meaning all participants will know they are receiving the treatment, and participants will be randomly assigned to different treatment groups to assess the anti-tumour activity of Roginolisib.
Study of RP-3500, Camonsertib, in Advanced Solid Tumors
This Phase 1/2a study, known as the TRESR Study, is investigating the safety, how the body processes and responds to the drug (pharmacokinetics and pharmacodynamics), and the early effectiveness of RP-3500 (camonsertib) in treating advanced solid tumours with specific genetic mutations. RP-3500 will be tested both on its own and in combination with talazoparib (a PARP inhibitor) or gemcitabine (a chemotherapy drug) to determine its potential in fighting tumours.
First in Human Study of T3P-Y058-739 (T3P)
This is the first trial in humans to test T3P-Y058-739, a genetically modified and weakened strain of the bacterium Yersinia enterocolitica. The study aims to find the right dose, test its safety, and see how well it works in people with advanced solid tumours.
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (DETERMINE)
DETERMINE is an open-label phase II/III trial. It will look at targeted treatments in rare cancers or common cancers with rare genetic change (mutation). Participants must have a cancer with an identified mutation. This could be found during routine testing or as part of another research programme.
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
The researchers are doing this study to find out whether the combination of axitinib and nivolumab is an effective and safe treatment for people with advanced or metastatic mucosal melanoma that has not been treated before.
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).